Recardio Inc., a clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the positive study results of Recardio's Phase 2 clinical study in Acute Myocardial Infarction were presented on Saturday, May 21, 2022, during the Latebreaker Session at the World Congress on Acute Heart Failure 2022 in Madrid.

Recardio Inc., a clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the study results of Recardio's Phase 2 clinical study in Acute Myocardial Infarction will be presented on Saturday, May 21, 2022, during the Latebreaker Session at the World Congress on Acute Heart Failure 2022 in Madrid.

Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases, announced the completion of its Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination with Filgrastim in Early Recovery Post-Myocardial Infarction.

Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its positive results of the interim analysis of Recardio's Phase II clinical trial in AMI were published in the latest release of the European Heart Journal. The current version of the journal relates to the presentation during the 2020 Congress of the European Society of Cardiology.

Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that the results of the interim analysis of Recardio's Phase II clinical trial will be presented at the 2020 Congress of the European Society of Cardiology from August 29 through September 1.

Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced publication of the outcomes of the Phase 1 clinical trial of its lead candidate dutogliptin. Entitled "Safety, tolerability, pharmacokinetics, and pharmacodynamics of parenterally administered dutogliptin: A prospective dose escalating trial", the article can be accessed here: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.14208

Recardio Inc., a clinical-stage life science company, announced that it has completed an interim analysis of its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction. Patient recruitment continues at all participating centers.

Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction is now enrolling and recruiting in all multiple European and U.S. centers.

Phase 2 is proud to announce the new client companies that have chosen to partner with us on their website, mobile application and custom business software projects.